ST葫芦娃：全资子公司广西维威制药有限公司获得依巴斯汀口服溶液药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Ebastine oral solution, which is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria [1] Group 1 - The full subsidiary of the company, Guangxi Weiwei Pharmaceutical Co., Ltd., is responsible for the newly approved Ebastine oral solution [1] - The Ebastine oral solution is suitable for treating allergic rhinitis (both seasonal and perennial) with or without allergic conjunctivitis, as well as chronic idiopathic urticaria [1]